Survodutide (BI 456906): Research Overview
Dual GLP-1 and glucagon receptor agonist in late-stage trials for obesity and liver disease.
Also known as BI 456906
What is Survodutide?
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
What is Survodutide researched for?
- 14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
- Superior to semaglutide: -8.7% vs -5.3% at 16 weeks.
- Dual mechanism addresses both energy intake and expenditure.
- 62% achieved MASH improvement without fibrosis worsening at 4.8mg.
- 63-67% achieved ≥30% liver fat reduction.
- HbA1c reduction up to -1.6% at highest doses.
How does Survodutide work?
Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
Reported targets: GLP-1R, GCGR
Pharmacokinetics
- Yes, the ~6-day half-life allows effective once-weekly dosing because peak levels remain therapeutic throughout the week. This contrasts with semaglutide (7-day half-life) - survodutide's slightly shorter half-life still covers the weekly interval adequately.
References
Phase 2 Obesity Trial Without Diabetes
2024
387 participants; BMI ≥27 kg/m²; 46 weeks. 14.9% mean weight loss at 4.8mg; 83% achieved ≥5%, 69% achieved ≥10%, 55% achieved ≥15%.
Controlled clinical trial
Phase 2 MASH and Fibrosis Trial
2024
293 participants with biopsy-confirmed MASH; 48 weeks. MASH improvement: 62% (4.8mg) vs 14% placebo; 63-67% achieved ≥30% liver fat reduction.
Controlled clinical trial
Phase 2 Type 2 Diabetes Trial
2023
Head-to-head vs semaglutide 1.0mg; 16 weeks. Survodutide -8.7% weight loss vs semaglutide -5.3%; HbA1c reduction up to -1.6%.
Controlled clinical trial
Common questions
Why is survodutide superior to semaglutide for weight loss?
Survodutide adds glucagon receptor agonism to GLP-1 effects, creating dual appetite suppression and energy expenditure increase. Head-to-head trials show -8.7% weight loss vs semaglutide's -5.3% at 16 weeks, because the glucagon pathway enhances fat burning independent of appetite.
Can survodutide reverse MASH (metabolic dysfunction-associated steatohepatitis)?
Yes, clinical trials show 62% of MASH patients achieved improvement without fibrosis worsening at 4.8mg weekly, with 63-67% achieving ≥30% liver fat reduction. This makes it one of the first investigational agents with FDA potential for both MASH treatment and weight loss.
Does survodutide cause heart rate increases like other GLP-1 drugs?
Survodutide shows a mean 2-5 bpm heart rate increase, similar to semaglutide. The glucagon receptor activation is modest enough to avoid significant tachycardia, though patients with cardiac conditions should monitor closely as with all GLP-1 agonists.